LLY vs NVO Comparison: AI Score, Valuation, Performance and Upside
LLY holds the edge across 4 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+58.86% vs +1.61%), though NVO has the better forward P/E setup (2.19x vs 25.50x for LLY). LLY leads on both revenue growth (55.50%) and operating margin (49.39%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for LLY (+11.15%) than for NVO (+0.12%).
| Metric | LLY | NVO |
|---|---|---|
| AI score | 74.7 | 39.7 |
| AI rank | #21 | #1104 |
| Latest close | $1,185.71 | $47.26 |
| 1M return | -2.48% | -3.33% |
| 6M return | +16.15% | +13.04% |
| 1Y return | +58.86% | +1.61% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | NVO |
|---|---|---|
| 1Y ago | $18.5K (+85.0%) started 2025-08-07 | $10.65K (+6.5%) started 2025-08-07 |
| 5Y ago | $48.12K (+381.2%) started 2021-08-09 | $11.68K (+16.8%) started 2021-08-09 |
| 10Y ago | $200.27K (+1902.7%) started 2016-08-08 | $32.6K (+226.0%) started 2016-08-08 |
Hypothetical — past performance does not guarantee future results.
| Metric | LLY | NVO |
|---|---|---|
| Market cap | $1.05T | $208.92B |
| Trailing P/E | 40.81 | 11.39 |
| Forward P/E | 25.50 | 2.19 |
| Price/Sales | 14.10 | 0.63 |
| EV/Revenue | 14.71 | 0.92 |
| Analyst target | $1,276.96 | $47.32 |
| Target upside | +11.15% | +0.12% |
| Metric | LLY | NVO |
|---|---|---|
| Revenue growth | 55.50% | 2.10% |
| Earnings growth | 169.90% | -20.60% |
| EPS growth | +169.90% | -20.60% |
| FCF margin | +12.67% | +11.44% |
| Operating margin | 49.39% | 42.54% |
| Profit margin | 34.99% | 35.35% |
| ROIC proxy | 107.46% | 59.81% |
| Return on equity | 107.46% | 59.81% |
| Dividend yield | 0.60% | 3.92% |
| Beta | 0.51 | 0.35 |
| Debt/equity | 139.01 | 63.33 |
| Current ratio | 1.50 | 0.87 |
| Quick ratio | 0.72 | 0.64 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | LLY | NVO |
|---|---|---|---|
| 1Y | Growth | +85.02% | +1.61% |
| CAGR | +85.18% | +1.61% | |
| Sharpe ratio | 1.78 | 0.17 | |
| Max drawdown | 23.31% | 43.67% | |
| Max daily drop | 7.79% | 16.43% | |
| Max wkly drop | 8.60% | 26.95% | |
| 5Y | Growth | +361.99% | +4.54% |
| CAGR | +35.85% | +0.89% | |
| Sharpe ratio | 0.97 | 0.10 | |
| Max drawdown | 34.48% | 74.70% | |
| Max daily drop | 14.14% | 21.83% | |
| Max wkly drop | 17.93% | 33.45% | |
| 10Y | Growth | +1595.65% | +152.51% |
| CAGR | +32.73% | +9.71% | |
| Sharpe ratio | 0.94 | 0.31 | |
| Max drawdown | 34.48% | 74.70% | |
| Max daily drop | 14.14% | 21.83% | |
| Max wkly drop | 17.93% | 33.45% |
| Category | LLY | NVO |
|---|---|---|
| Company | LLY | NVO |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.